Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and Trastuzumab in HER2-positive Metastatic Breast Cancer
NCT00320385Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of lapatinib in HER2-positive breast cancer, breast cancer, sponsored by GSK. Started Nov 2005; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancerbreast cancer
Beyond the preview
Go deeper on NCT00320385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320385.